Single-cell technologies allow the examination of differences between individual cells instead of the averaged signal obtained is the case of bulk samples.
Global Single-Cell Analysis Market is estimated at $2.1 Bn (2020) growing at a CAGR of 17.8% through 2020-2025. The expansion of oncology and life science research is the factor driving the market growth.
Single-cell analysis: A potential oncology research tool
Single-cell analysis is emerging as powerful tool for cancer research. It characterizes the molecular state of each tumor cell, enabling exploration of tumor heterogeneity, microenvironment cell-type composition, and cell state transitions that affect therapeutic response, particularly in the context of immunotherapy. The demand for products used in single-cell analysis is projected to increase due to the increased incidence of various forms of cancer and the expansion of cancer research projects.
“Bulk sequencing can explain the most common mutations in tumor, but single-cell DNA multi-omics offer insights on which mutations occur at single-cell level. Drug developers are increasingly using single-cell analysis to prioritize targets and pathways for new therapies, demonstrate therapeutic efficacy, and understand resistance mechanisms” – Global Research Head, Leading Pharmaceutical Company
Investor funding is providing impetus for single-cell technology
Single-cell analysis has become a vital tool for scientific research. Investors are providing funding to companies that are developing products or solutions for single-cell analysis, citing the potential for advancement.
In November 2021, Singleron Biotechnologies, a start-up company developing single-cell multi-omics products – raised $100 million to ramp up products development and augment international presence.
Further, in October 2021, Sphere Fluidics received $40 million to expand international sales activities for its single-cell analysis systems that use proprietary picodroplet technology.
Explore Premium Report on Single-Cell Analysis Market @ https://meditechinsights.com/single-cell-analysis-market/
Analysis of complex and richer datasets may present challenge
In comparison to bulk sequencing, single-cell sequencing methods generate datasets that are more complex and richer. The increased complexity might result in misunderstandings and wrong conclusions. However, advances in data analytics as well as the use of machine learning/AI to data analysis are increasingly being used to overcome these challenges.
Regional Adoption: Single-Cell Analysis Market
Comprehensive regional assessment of the global single-cell analysis market suggests that US is currently the largest market for single-cell analysis. The U.S. has a large number of biotech companies and research institutions, and it enjoys greater funding for life science research. Also, the U.S. led global VC investment in biotech sector in 2020, followed by Europe and China. The Asia-Pacific single-cell analysis market dominated by China is expanding more quickly compared to other regions.
Competitive Landscape Analysis of Single-Cell Analysis Market
Some of the key players in global single-cell analysis market are Becton, Dickinson and Company, Danaher, Merck, Thermo Fisher, Qiagen, 10X Genomics, Fluidigm, Promega, Illumina, Bio-Rad Laboratories, and Luminex.
For More Comprehensive Insights, Contact Us @ https://meditechinsights.com/contact-us/
About Medi-Tech Insights
Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services.
Associate, Medi-Tech Insights
+32 498 86 80 79